Customer Validation
Successful use cases by our biotech customers
Simbec-Orion is a full-service CRO and a strategic partner of biotx.ai. The partnership with biotx.ai has led Simbec-Orion to new contracts worth $35M, beating competitors such as iQuvia, Medpace and Syneos in 2024.
Refoxy Pharma, a pharmaceutical company focused on longevity and the treatment of age-associated diseases, used the biotx.ai platform to identify promising indications for a particular drug target of interest. The results of causal modeling helped Refoxy to secure a €20M investment for a phase I clinical trial.
Samsara Therapeutics, an Oxford-based biotechnology firm focused on neurodegenerative diseases, used the biotx.ai platform to identify the causal effects of a specific compound on a number of biomarkers, which in turn informed the selection of potential indications and became key measures of interest in clinical development research.
3Z Pharmaceuticals, a Iceland-based biotechnology firm conducting research on central nervous system disorders, partnered with biotx.ai and obtained causal evidence from human genetic data to support a novel, non-stimulant treatment for ADHD that they had previously shown to reduce hyperactivity in animal models. A joint publication is under review.
Nucleome Therapeutics, an Oxford-based biotechnology firm focused on autoimmune diseases, found that two drug targets of interest were not supported by our causal inference platform for the treatment of the diseases under investigation but did find a causal effect of another drug target on Lupus and further identified a number of biomarkers with causal effects on Lupus and Rheumatoid Arthritis.
Immungentics, a German biotechnology firm focused on Alzheimerʼs disease, was able not only to find causal biomarkers crucial for their study design, but in addition, used multiple causal models from biotx.aiʼs analyses to better understand the exact mode of action of their drug thiethylperazine via the ABCC1 transporter.
Alfa Intes, a family-owned Italian pharmaceutical company, discovered new indications for their drug Indomethacin through our platform and is in the process of selecting an indication for a further deal with biotx.ai.
Eternygen, a German biotechnology firm, found via our platform that a compound under development was unlikely to demonstrate efficacy as a treatment for a particular indication of interest and has shifted focus onto another more-promising indication instead and has meanwhile signed a deal for further work with biotx.ai.
